Histogen to Present at the H.C. Wainwright Global Investment Conference
May 17 2022 - 4:05PM
Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company
focused on developing both restorative therapeutics and pan-caspase
and caspase selective inhibitors focused on treatments for
infectious and inflammatory diseases, today announced that Steven
J. Mento, Ph.D., Histogen’s Executive Chairman and Interim
President and Chief Executive Officer, will present at the H.C.
Wainwright Global Investment Conference.
On-Demand Presentation DetailsDate: Tuesday,
May 24, 2022Time: 7:00 a.m. Eastern Time (4:00 a.m. Pacific
Time)Webcast
Link: https://journey.ct.events/view/28269575-27c6-405a-8df1-1ae417047e5a
The on-demand presentation will be archived for 90 days and
available through the Investors page on www.histogen.com.
About Histogen Inc.
Histogen Inc. is a clinical-stage therapeutics
company focused on developing both potential first-in-class
restorative therapeutics that ignite the body’s natural process to
repair and maintain healthy biological function as well as a
pipeline of clinical and preclinical small molecule pan-caspase and
caspase selective inhibitors focused on treatments for infectious
and inflammatory diseases. Under our biologics technology platform,
our product candidates in development are HST-003, a treatment for
joint cartilage repair, and HST-004, a treatment for spinal disc
repair. In addition, within our small molecule pipeline, our
product candidates include emricasan, CTS-2090 and CTS-2096.
Currently, emricasan is being developed jointly with our
collaboration partner, Amerimmune, for the treatment of COVID-19,
and we are evaluating the use of emricasan for other infectious
diseases including the treatment of MRSA. We also have preclinical
product candidates, CTS-2090 and CTS-2096, novel, potent, orally
bioavailable, and highly selective small molecule inhibitors of
caspase-1 designed for the treatment of certain inflammatory
diseases. For more information, please visit www.histogen.com.
CONTACT:
Susan A. KnudsonExecutive Vice President & CFO Histogen Inc.
ir@histogen.com
Histogen (NASDAQ:HSTO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Histogen (NASDAQ:HSTO)
Historical Stock Chart
From Apr 2023 to Apr 2024